NLRP2
Basic information
Region (hg38): 19:54953130-55001142
Previous symbols: [ "NALP2" ]
Links
Phenotypes
GenCC
Source:
- oocyte/zygote/embryo maturation arrest 18 (Limited), mode of inheritance: Unknown
Clinical Genomic Database
Source:
Condition | Inheritance | Intervention Categories | Intervention/Rationale | Manifestation Categories | References |
---|---|---|---|---|---|
Oocyte/zygote/embryo maturation arrest 18 | AR | Obstetric | Some individuals have been described as able to achieve successful pregnancies using IVF | Obstetric | 30877238 |
ClinVar
This is a list of variants' phenotypes submitted to
Variants pathogenicity by type
Statistics on ClinVar variants can assist in determining whether a specific variant type in the NLRP2 gene is commonly pathogenic or not.
In the table, we include only reliable ClinVar variants with their consequences to MANE Select, Mane Plus Clinical transcripts, or transcripts with TSL equals 1. Click the count to view the source variants.
Warning: slight differences between displayed counts and the number of variants in ClinVar may occur, primarily due to (1) the application of a different transcript and/or consequence by our variant effect predictor or (2) differences in clinical significance: we classify Benign/Likely benign variants as Likely benign and Pathogenic/Likely pathogenic variants as Likely pathogenic.
Variant type | Pathogenic | Likely pathogenic | VUS | Likely benign | Benign | Sum |
---|---|---|---|---|---|---|
synonymous | 56 | 11 | 68 | |||
missense | 75 | 29 | 14 | 118 | ||
nonsense | 1 | |||||
start loss | 0 | |||||
frameshift | 1 | |||||
inframe indel | 0 | |||||
splice donor/acceptor (+/-2bp) | 1 | |||||
splice region | 2 | 3 | 2 | 7 | ||
non coding | 1 | |||||
Total | 0 | 1 | 78 | 85 | 26 |
Variants in NLRP2
This is a list of pathogenic ClinVar variants found in the NLRP2 region.
You can filter this list by clicking the number of variants in the Variants pathogenicity by type table.
Position | Type | Phenotype | Significance | ClinVar |
---|---|---|---|---|
19-54970023-C-T | not specified | Uncertain significance (Apr 14, 2022) | ||
19-54970026-C-T | NLRP2-related disorder | Benign (Dec 31, 2019) | ||
19-54970029-C-T | not specified | Uncertain significance (Jun 24, 2022) | ||
19-54970030-G-A | NLRP2-related disorder | Benign (Oct 25, 2019) | ||
19-54970087-C-G | NLRP2-related disorder | Benign (Nov 14, 2019) | ||
19-54970107-C-T | not specified | Uncertain significance (Sep 27, 2021) | ||
19-54970118-C-T | NLRP2-related disorder | Likely benign (May 01, 2022) | ||
19-54970126-C-G | not specified | Uncertain significance (May 23, 2023) | ||
19-54970127-G-A | not specified | Uncertain significance (May 05, 2022) | ||
19-54970155-T-C | Uncertain significance (Jul 11, 2024) | |||
19-54970162-G-A | NLRP2-related disorder | Likely benign (Aug 01, 2022) | ||
19-54970228-G-A | NLRP2-related disorder | Likely benign (Jun 17, 2019) | ||
19-54970254-A-C | not provided (-) | |||
19-54970255-C-G | not specified | Uncertain significance (Apr 28, 2023) | ||
19-54970302-G-A | NLRP2-related disorder | Likely benign (Dec 01, 2022) | ||
19-54970388-C-A | not provided (-) | |||
19-54970515-C-T | not provided (-) | |||
19-54974480-C-T | not provided (-) | |||
19-54974542-T-C | not specified | Uncertain significance (Aug 12, 2024) | ||
19-54974547-A-C | not provided (-) | |||
19-54974673-G-A | not provided (-) | |||
19-54977684-A-G | not provided (-) | |||
19-54977761-G-A | not specified | Uncertain significance (Jan 23, 2024) | ||
19-54977783-C-T | NLRP2-related disorder | Likely benign (Dec 31, 2019) | ||
19-54977784-G-A | not specified | Uncertain significance (Nov 08, 2022) |
GnomAD
Source:
Gene | Type | Bio Type | Transcript | Coding Exons | Length |
---|---|---|---|---|---|
NLRP2 | protein_coding | protein_coding | ENST00000543010 | 12 | 48013 |
pLI Probability LOF Intolerant | pRec Probability LOF Recessive | Individuals with no LOFs | Individuals with Homozygous LOFs | Individuals with Heterozygous LOFs | Defined | p |
---|---|---|---|---|---|---|
1.42e-38 | 1.21e-7 | 125464 | 1 | 283 | 125748 | 0.00113 |
Z-Score | Observed | Expected | Observed/Expected | Mutation Rate | Total Possible in Transcript | |
---|---|---|---|---|---|---|
Missense | -2.35 | 750 | 590 | 1.27 | 0.0000373 | 6952 |
Missense in Polyphen | 183 | 161.88 | 1.1304 | 2158 | ||
Synonymous | -4.82 | 360 | 261 | 1.38 | 0.0000188 | 2086 |
Loss of Function | -1.13 | 53 | 44.8 | 1.18 | 0.00000264 | 505 |
LoF frequencies by population
Ethnicity | Sum of pLOFs | p |
---|---|---|
African & African-American | 0.00232 | 0.00213 |
Ashkenazi Jewish | 0.0000992 | 0.0000992 |
East Asian | 0.000652 | 0.000653 |
Finnish | 0.000647 | 0.000647 |
European (Non-Finnish) | 0.00132 | 0.00131 |
Middle Eastern | 0.000652 | 0.000653 |
South Asian | 0.00176 | 0.00170 |
Other | 0.000978 | 0.000978 |
dbNSFP
Source:
- Function
- FUNCTION: Suppresses TNF- and CD40-induced NFKB1 activity at the level of the IKK complex, by inhibiting NFKBIA degradation induced by TNF. When associated with PYCARD, activates CASP1, leading to the secretion of mature proinflammatory cytokine IL1B. May be a component of the inflammasome, a protein complex which also includes PYCARD, CARD8 and CASP1 and whose function would be the activation of proinflammatory caspases. {ECO:0000269|PubMed:15456791}.;
- Pathway
- Nucleotide-binding Oligomerization Domain (NOD) pathway
(Consensus)
Recessive Scores
- pRec
- 0.128
Intolerance Scores
- loftool
- 0.955
- rvis_EVS
- 1.2
- rvis_percentile_EVS
- 92.96
Haploinsufficiency Scores
- pHI
- 0.843
- hipred
- N
- hipred_score
- 0.112
- ghis
- 0.469
Essentials
- essential_gene_CRISPR
- N
- essential_gene_CRISPR2
- N
- essential_gene_gene_trap
- N
- gene_indispensability_pred
- E
- gene_indispensability_score
- 0.827
Gene Damage Prediction
All | Recessive | Dominant | |
---|---|---|---|
Mendelian | Medium | Medium | Medium |
Primary Immunodeficiency | Medium | Medium | Medium |
Cancer | Medium | Medium | Medium |
Mouse Genome Informatics
- Gene name
- Nlrp2
- Phenotype
Gene ontology
- Biological process
- apoptotic process;inflammatory response;negative regulation of NF-kappaB transcription factor activity;positive regulation of cysteine-type endopeptidase activity involved in apoptotic process;innate immune response;positive regulation of interleukin-1 beta secretion
- Cellular component
- nuclear chromosome, telomeric region;cytoplasm;Golgi apparatus;cytosol;intracellular membrane-bounded organelle
- Molecular function
- protein binding;ATP binding;Pyrin domain binding